136 related articles for article (PubMed ID: 31487747)
1. Visfatin Levels May be an Early Marker of Atherosclerosis in Patients with Acromegaly.
Piskinpasa H; Okuturlar Y; Dogansen SC; Akdeniz YS; Esen A; Sadri S; Pirhan O; Gemici AA; Serin SO; Gedikbası A; Adas M; Mert M
Horm Metab Res; 2019 Oct; 51(10):649-654. PubMed ID: 31487747
[TBL] [Abstract][Full Text] [Related]
2. Adipocytes as a source of increased circulating levels of nicotinamide phosphoribosyltransferase/visfatin in active acromegaly.
Olarescu NC; Ueland T; Lekva T; Dahl TB; Halvorsen B; Aukrust P; Bollerslev J
J Clin Endocrinol Metab; 2012 Apr; 97(4):1355-62. PubMed ID: 22319029
[TBL] [Abstract][Full Text] [Related]
3. A link between bone mineral density and serum adiponectin and visfatin levels in acromegaly.
Sucunza N; Barahona MJ; Resmini E; Fernández-Real JM; Ricart W; Farrerons J; Rodríguez Espinosa J; Marin AM; Puig T; Webb SM
J Clin Endocrinol Metab; 2009 Oct; 94(10):3889-96. PubMed ID: 19723758
[TBL] [Abstract][Full Text] [Related]
4. Is elevated urotensin II level a predictor for increased cardiovascular risk in subjects with acromegaly?
Demirpence M; Guler A; Yilmaz H; Sayin A; Pekcevik Y; Turkon H; Colak A; Ari EM; Aslanipour B; Kocabas GU; Calan M
J Endocrinol Invest; 2019 Feb; 42(2):207-215. PubMed ID: 29804270
[TBL] [Abstract][Full Text] [Related]
5. Increased circulating levels of irisin are associated with cardiovascular risk factors in subjects with acromegaly.
Calan M; Demirpence M
Hormones (Athens); 2019 Dec; 18(4):435-442. PubMed ID: 31696447
[TBL] [Abstract][Full Text] [Related]
6. Divergence between growth hormone and insulin-like growth factor-i concentrations in the follow-up of acromegaly.
Alexopoulou O; Bex M; Abs R; T'Sjoen G; Velkeniers B; Maiter D
J Clin Endocrinol Metab; 2008 Apr; 93(4):1324-30. PubMed ID: 18230660
[TBL] [Abstract][Full Text] [Related]
7. Serum visfatin levels in acromegaly: Correlation with disease activity and metabolic alterations.
Ciresi A; Amato MC; Pizzolanti G; Giordano C
Growth Horm IGF Res; 2015 Oct; 25(5):240-6. PubMed ID: 26188992
[TBL] [Abstract][Full Text] [Related]
8. Low serm Fibroblast Growth Factor-21 levels is not associated with Carotid intima-media thickness in acromegaly patients.
Uygur MM; Dereli Yazıcı D; Gogas Yavuz D
J Endocrinol Invest; 2022 Jul; 45(7):1405-1412. PubMed ID: 35334074
[TBL] [Abstract][Full Text] [Related]
9. The relationship of serum visfatin levels with clinical parameters, flow-mediated dilation, and carotid intima-media thickness in patients with ankylosing spondylitis.
Aydoğan Baykara R; Küçük A; Tuzcu A; Tuzcu G; Cüre E; Uslu AU; Omma A
Turk J Med Sci; 2021 Aug; 51(4):1865-1874. PubMed ID: 33754654
[TBL] [Abstract][Full Text] [Related]
10. Markers of early atherosclerosis, oxidative stress and inflammation in patients with acromegaly.
Ozkan C; Altinova AE; Cerit ET; Yayla C; Sahinarslan A; Sahin D; Dincel AS; Toruner FB; Akturk M; Arslan M
Pituitary; 2015 Oct; 18(5):621-9. PubMed ID: 25500981
[TBL] [Abstract][Full Text] [Related]
11. Visfatin (nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes.
Kadoglou NP; Sailer N; Moumtzouoglou A; Kapelouzou A; Tsanikidis H; Vitta I; Karkos C; Karayannacos PE; Gerasimidis T; Liapis CD
Exp Clin Endocrinol Diabetes; 2010 Feb; 118(2):75-80. PubMed ID: 19834878
[TBL] [Abstract][Full Text] [Related]
12. Three noninvasive methods in the evaluation of subclinical cardiovascular disease in patients with acromegaly: epicardial fat thickness, aortic stiffness and serum cell adhesion molecules.
Topaloglu O; Sayki Arslan M; Turak O; Ginis Z; Sahin M; Cebeci M; Ucan B; Cakir E; Karbek B; Ozbek M; Cakal E; Delibasi T
Clin Endocrinol (Oxf); 2014 May; 80(5):726-34. PubMed ID: 24164445
[TBL] [Abstract][Full Text] [Related]
13. Procalcitonin can be used as a marker of premature atherosclerosis in acromegaly.
Ozkan H; Celik O; Hatipoglu E; Kantarci F; Kadioglu P
Pituitary; 2012 Sep; 15(3):358-64. PubMed ID: 21735088
[TBL] [Abstract][Full Text] [Related]
14. Adequacy of current postglucose GH nadir limit (< 1 microg/l) to define long-lasting remission of acromegalic disease.
Ronchi CL; Arosio M; Rizzo E; Lania AG; Beck-Peccoz P; Spada A
Clin Endocrinol (Oxf); 2007 Apr; 66(4):538-42. PubMed ID: 17371472
[TBL] [Abstract][Full Text] [Related]
15. Effects of atorvastatin on apelin, visfatin (nampt), ghrelin and early carotid atherosclerosis in patients with type 2 diabetes.
Kadoglou NP; Sailer N; Kapelouzou A; Lampropoulos S; Vitta I; Kostakis A; Liapis CD
Acta Diabetol; 2012 Aug; 49(4):269-76. PubMed ID: 21748474
[TBL] [Abstract][Full Text] [Related]
16. [Lowered ghrelin levels in acromegaly—normalization after treatment].
Kozakowski J; Rabijewski M; Zgliczyński W
Endokrynol Pol; 2005; 56(6):862-70. PubMed ID: 16821203
[TBL] [Abstract][Full Text] [Related]
17. "Subclinical atherosclerosis in acromegaly: Possible association with cardiovascular risk factors rather than disease activity".
de Almeida MCC; Freire CMV; Nunes MDCP; Soares BS; Barbosa MM; Giannetti AV; Zille GP; Miranda PAC; Ribeiro-Oliveira A; Drummond JB
Growth Horm IGF Res; 2022 Feb; 62():101442. PubMed ID: 34952478
[TBL] [Abstract][Full Text] [Related]
18. The value of visfatin in the prediction of metabolic syndrome: a multi-factorial analysis.
Esteghamati A; Morteza A; Zandieh A; Jafari S; Rezaee M; Nakhjavani M; Jamali A; Esteghamati AR; Khalilzadeh O
J Cardiovasc Transl Res; 2012 Aug; 5(4):541-6. PubMed ID: 22585407
[TBL] [Abstract][Full Text] [Related]
19. ASSESSMENT OF DIASTOLIC DYSFUNCTION, ARTERIAL STIFFNESS, AND CAROTID INTIMA-MEDIA THICKNESS IN PATIENTS WITH ACROMEGALY.
Cansu GB; Yılmaz N; Yanıkoğlu A; Özdem S; Yıldırım AB; Süleymanlar G; Altunbaş HA
Endocr Pract; 2017 May; 23(5):536-545. PubMed ID: 28156155
[TBL] [Abstract][Full Text] [Related]
20. Visfatin is related to lipid dysregulation, endothelial dysfunction and atherosclerosis in patients with chronic kidney disease.
Mu J; Feng B; Ye Z; Yuan F; Zeng W; Luo Z; Qi W
J Nephrol; 2011; 24(2):177-84. PubMed ID: 20602330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
